Biotage publishes prospectus for admission to trading of shares, to be issued as part of the acquisition of Astrea Bioseparations, on Nasdaq Stockholm

Uppsala, Sweden – 30 May 2023 – As previously announced, Biotage AB (publ) (“Biotage”) has entered into agreements to acquire all of the shares in Astrea Bioseparations (“Astrea”) from Gamma Biosciences (“Gamma”) [1], a life sciences tools platform created by KKR. The acquisition also includes the shares held by certain minority investors [2] in the Astrea group (together with Gamma, the “Sellers”, and together with the acquisition of Astrea, the “Transaction”). The Transaction is expected to be completed on or around 1 June 2023. As part consideration for the Transaction, the board of directors of Biotage will, by virtue of an authorization granted by the Annual General Meeting held on 27 April 2023, resolve to issue 13,954,103 ordinary shares to the Sellers.

A prospectus regarding admission to trading of the ordinary shares, to be issued as part of the Transaction, on Nasdaq Stockholm, has been approved and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website, www.biotage.com.

About Biotage
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.

Website: www.biotage.com

Contacts
Tomas Blomquist, President and CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com

The information was submitted for publication, through the agency of the contact person set out above, at 2023-05-30 10:50 CEST.

[1] Held through Gamma Biosciences Newco Limited and Gamma Biosciences Newco 2 Limited, two entities controlled by KKR.
[2] Held through Nano Hold Co., LLC.